|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ATP5F1A |
Gene summary for ATP5F1A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ATP5F1A | Gene ID | 498 |
| Gene name | ATP synthase F1 subunit alpha | |
| Gene Alias | ATP5A | |
| Cytomap | 18q21.1 | |
| Gene Type | protein-coding | GO ID | GO:0001667 | UniProtAcc | P25705 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 498 | ATP5F1A | GSM4909281 | Human | Breast | IDC | 4.78e-03 | 2.77e-01 | 0.21 |
| 498 | ATP5F1A | GSM4909282 | Human | Breast | IDC | 3.21e-09 | 5.11e-01 | -0.0288 |
| 498 | ATP5F1A | GSM4909285 | Human | Breast | IDC | 2.51e-20 | 5.76e-01 | 0.21 |
| 498 | ATP5F1A | GSM4909286 | Human | Breast | IDC | 6.91e-17 | 2.26e-01 | 0.1081 |
| 498 | ATP5F1A | GSM4909287 | Human | Breast | IDC | 2.74e-04 | 3.23e-01 | 0.2057 |
| 498 | ATP5F1A | GSM4909290 | Human | Breast | IDC | 5.19e-04 | 2.39e-01 | 0.2096 |
| 498 | ATP5F1A | GSM4909293 | Human | Breast | IDC | 4.07e-08 | 3.04e-01 | 0.1581 |
| 498 | ATP5F1A | GSM4909295 | Human | Breast | IDC | 3.01e-02 | 3.08e-01 | 0.0898 |
| 498 | ATP5F1A | GSM4909297 | Human | Breast | IDC | 5.56e-04 | 1.72e-01 | 0.1517 |
| 498 | ATP5F1A | GSM4909298 | Human | Breast | IDC | 1.64e-04 | 1.13e-01 | 0.1551 |
| 498 | ATP5F1A | GSM4909299 | Human | Breast | IDC | 7.85e-03 | 2.62e-01 | 0.035 |
| 498 | ATP5F1A | GSM4909300 | Human | Breast | IDC | 2.01e-04 | 3.56e-01 | 0.0334 |
| 498 | ATP5F1A | GSM4909304 | Human | Breast | IDC | 2.40e-02 | 2.37e-01 | 0.1636 |
| 498 | ATP5F1A | GSM4909305 | Human | Breast | IDC | 8.54e-14 | 4.86e-01 | 0.0436 |
| 498 | ATP5F1A | GSM4909306 | Human | Breast | IDC | 3.58e-02 | 2.76e-01 | 0.1564 |
| 498 | ATP5F1A | GSM4909308 | Human | Breast | IDC | 5.08e-05 | 1.42e-01 | 0.158 |
| 498 | ATP5F1A | GSM4909311 | Human | Breast | IDC | 2.35e-15 | -2.79e-01 | 0.1534 |
| 498 | ATP5F1A | GSM4909317 | Human | Breast | IDC | 2.11e-11 | 3.38e-01 | 0.1355 |
| 498 | ATP5F1A | GSM4909319 | Human | Breast | IDC | 1.51e-25 | -1.37e-01 | 0.1563 |
| 498 | ATP5F1A | GSM4909320 | Human | Breast | IDC | 2.14e-02 | -3.66e-01 | 0.1575 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000611911 | Stomach | CAG with IM | oxidative phosphorylation | 46/1050 | 141/18723 | 2.12e-23 | 3.76e-20 | 46 |
| GO:000609111 | Stomach | CAG with IM | generation of precursor metabolites and energy | 86/1050 | 490/18723 | 1.45e-21 | 1.93e-18 | 86 |
| GO:000906011 | Stomach | CAG with IM | aerobic respiration | 49/1050 | 189/18723 | 5.39e-20 | 5.75e-17 | 49 |
| GO:004533311 | Stomach | CAG with IM | cellular respiration | 54/1050 | 230/18723 | 9.39e-20 | 8.34e-17 | 54 |
| GO:001598011 | Stomach | CAG with IM | energy derivation by oxidation of organic compounds | 64/1050 | 318/18723 | 1.96e-19 | 1.49e-16 | 64 |
| GO:001598511 | Stomach | CAG with IM | energy coupled proton transport, down electrochemical gradient | 16/1050 | 26/18723 | 2.67e-14 | 1.30e-11 | 16 |
| GO:001598611 | Stomach | CAG with IM | ATP synthesis coupled proton transport | 16/1050 | 26/18723 | 2.67e-14 | 1.30e-11 | 16 |
| GO:190260011 | Stomach | CAG with IM | proton transmembrane transport | 34/1050 | 157/18723 | 7.15e-12 | 2.38e-09 | 34 |
| GO:000914411 | Stomach | CAG with IM | purine nucleoside triphosphate metabolic process | 25/1050 | 88/18723 | 8.00e-12 | 2.40e-09 | 25 |
| GO:000920611 | Stomach | CAG with IM | purine ribonucleoside triphosphate biosynthetic process | 22/1050 | 68/18723 | 8.10e-12 | 2.40e-09 | 22 |
| GO:000920511 | Stomach | CAG with IM | purine ribonucleoside triphosphate metabolic process | 24/1050 | 82/18723 | 1.03e-11 | 2.76e-09 | 24 |
| GO:000914511 | Stomach | CAG with IM | purine nucleoside triphosphate biosynthetic process | 22/1050 | 69/18723 | 1.13e-11 | 2.86e-09 | 22 |
| GO:000675411 | Stomach | CAG with IM | ATP biosynthetic process | 20/1050 | 57/18723 | 1.32e-11 | 3.14e-09 | 20 |
| GO:004277611 | Stomach | CAG with IM | mitochondrial ATP synthesis coupled proton transport | 12/1050 | 19/18723 | 3.18e-11 | 6.78e-09 | 12 |
| GO:000920111 | Stomach | CAG with IM | ribonucleoside triphosphate biosynthetic process | 22/1050 | 74/18723 | 5.34e-11 | 1.09e-08 | 22 |
| GO:000919911 | Stomach | CAG with IM | ribonucleoside triphosphate metabolic process | 24/1050 | 89/18723 | 7.02e-11 | 1.34e-08 | 24 |
| GO:000914211 | Stomach | CAG with IM | nucleoside triphosphate biosynthetic process | 23/1050 | 85/18723 | 1.62e-10 | 2.98e-08 | 23 |
| GO:000683911 | Stomach | CAG with IM | mitochondrial transport | 42/1050 | 254/18723 | 2.58e-10 | 4.44e-08 | 42 |
| GO:000914111 | Stomach | CAG with IM | nucleoside triphosphate metabolic process | 26/1050 | 112/18723 | 4.23e-10 | 6.83e-08 | 26 |
| GO:000915011 | Stomach | CAG with IM | purine ribonucleotide metabolic process | 48/1050 | 368/18723 | 4.36e-08 | 3.32e-06 | 48 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
| hsa0502016 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
| hsa0501616 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
| hsa0019016 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
| hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0501416 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
| hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
| hsa0520818 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
| hsa0471418 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
| hsa0541518 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
| hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
| hsa0502017 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
| hsa0501617 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
| hsa0019017 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
| hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0501417 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
| hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
| hsa0520819 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
| hsa0471419 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
| hsa0541519 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |